Sunshine Nuohe released its 2026 interim report. Total operating revenue was 426 million yuan, down 27.81 percent year on year. Net profit attributable to the parent swung to a loss of 24.4 million yuan, a decrease of 154 million yuan from the same period last year, down 118.79 percent year on year. Net cash flow from operating activities was negative 51.53 million yuan, down 161.25 percent year on year. The company's asset-liability ratio was 46.30 percent, gross margin was 49.19 percent, return on equity was negative 2.03 percent, and diluted earnings per share was negative 0.22 yuan.
Beijing Sun Novo Pharmaceutical Research Co LtdCompany swung to a net loss of 24.4 million yuan in its 2026 interim report, with revenue down 27.81% year on year.